VSTM

AI MemoPost-earnings T+1

Verastem

As of 2026-05-08/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

RAMP 205 pancreatic update is a near-term clinical checkpoint • 2026-08-06

Expected move: +16%

Biggest risk

The T+1 setup remains fragile because the 10-Q includes explicit going-concern language even after the launch ramp, and the stock traded about 14% below the May 7 close during May 8 trading, suggesting investors prioritized financing and burn risk over the revenue print. No robust T+1 analyst target-change or estimate-revision signal was confirmed from primary or trusted follow-up sources, so conviction should stay moderate rather than upgraded.

Invalidation

Break below $3 or thesis failure.

What would change my mind?

The cleanest positive read-through is that AVMAPKI FAKZYNJA CO-PACK is generating real commercial revenue, with the May 2026 presentation citing about $50 million of cumulative net product revenue since launch, 400+ unique U.S. prescribers through April 2026, and management’s view that the franchise can become self-sustaining in 2H 2026 [#8-K-2026-05-07]. Near-term clinical catalysts in RAMP 205 and VS-7375 add optionality on top of the launch.

Research note

Recommendation

—

Confidence

medium

As of

2026-05-08

Base target

p=45%

Bull target

$11

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings digestion is centered on launch traction versus funding risk
VS-7375 early data and registration-directed path remain the main upside lever
The cleanest positive read-through is that AVMAPKI FAKZYNJA CO-PACK is generating real commercial revenue, with the May 2026 presentation citing about $50 million of cumulative net product revenue since launch, 400+ unique U.S.

BearKey bullets

Coverage is low and the peer set is loose, so the post-earnings read-through has less external validation than a higher-coverage biotech and should be treated as a monitoring view rather than a high-conviction rerating call.
Quarterly operating expenses remained high versus revenue, with $38.2 million of R&D and $22.3 million of selling, general and administrative expense against $18.7 million of product revenue in Q1 2026 [#10-Q-2026-05-07].
The March 31, 2026 10-Q says substantial doubt exists about Verastem’s ability to continue as a going concern for twelve months after issuance if additional capital or sufficient commercialization progress does not materialize [#10-Q-2026-05-07].

WatchKey bullets

RAMP 205 pancreatic update is a near-term clinical checkpoint

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $7 (p=45%)

Bull/Bear spread: +81% / -44%

Vs latest close: Bull +81% · Base +16% · Bear -44%

Scenario probabilities

Bull Target: $11 (p=25%)Base Target: $7 (p=45%)Bear Target: $3 (p=30%)

Commentary

Tone is mixed-to-negative on a T+1 basis. The company delivered a legitimate commercial revenue print and reiterated multiple 2026 data milestones through its May 7 materials, but live market pricing on May 8 showed a roughly 14% drop from the May 7 close of $5.66 to about $4.87, implying the market focused more on financing runway, burn, and the going-concern disclosure than on the topline launch progression. Analyst revision evidence was not clearly available yet, which supports cautious monitoring language rather than a stronger post-earnings upgrade.

As of 2026-05-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings digestion is centered on launch traction versus funding risk
VS-7375 early data and registration-directed path remain the main upside lever

Scenarios

Bull Target (Scenario probability)

$11 / p=25% prob

Base Target (Scenario probability)

$7 / p=45% prob

Bear Target (Scenario probability)

$3 / p=30% prob

Price $6 as of 2026-08-04

Nearest Scenario: Base (∆ 16%)

Targets vs latest close: Bull +81% · Base +16% · Bear -44%

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-06
RAMP 205 pancreatic update is a near-term clinical checkpoint
The May 2026 corporate presentation furnished with the May 7, 2026 8-K says Verastem expects a Q2 2026 update on the safety and efficacy of the RAMP 205 expansion cohort with six months of follow-up on all patients, making this one of the clearest upcoming data events [#8-K-2026-05-07].
Prob 65.00% • Move 25.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Post-earnings digestion is centered on launch traction versus funding risk
2026-05-08
Q1 2026 product revenue was $18.671 million, net loss narrowed to $36.6 million, and cash, cash equivalents and restricted cash ended the quarter at $165.8 million, but the 10-Q also states substantial doubt about the company’s ability to continue as a going concern within twelve months absent additional capital or sufficient commercialization progress [#10-Q-2026-05-07].
Prob 80% • Move 12% • Priced-in 55%

Long-term Catalysts

Months to a year

VS-7375 early data and registration-directed path remain the main upside lever
2027-05-08
The May 2026 corporate presentation says Verastem expects an early 1H 2026 data update from TARGET-D 101 for VS-7375 and is targeting first-patient-in around mid-2026 for TARGET-D 201, 202 and 203, which could define whether the KRAS G12D program supports a broader rerating beyond the current AVMAPKI launch story [#8-K-2026-05-07].
Prob 55% • Move 35% • Priced-in 20%

Risks

Coverage is low and the peer set is loose, so the post-earnings read-through has less external validation than a higher-coverage biotech and should be treated as a monitoring view rather than a high-conviction rerating call.
Quarterly operating expenses remained high versus revenue, with $38.2 million of R&D and $22.3 million of selling, general and administrative expense against $18.7 million of product revenue in Q1 2026 [#10-Q-2026-05-07].
The March 31, 2026 10-Q says substantial doubt exists about Verastem’s ability to continue as a going concern for twelve months after issuance if additional capital or sufficient commercialization progress does not materialize [#10-Q-2026-05-07].
The core bullish thesis still depends on continued AVMAPKI uptake and on clinical execution in RAMP 205 and VS-7375; disappointing data, slower adoption, reimbursement friction, or timeline slippage would likely pressure the shares.

Peers

Symbol	Summary
AQST	Aquestive is a similarly sized biotech by market cap, but the business mix and modality are different; it is only a loose small-cap biotech risk-appetite comp rather than a direct oncology-commercial peer.
AURA	Aura is another small-cap biotech with clinical and financing sensitivity, but it is not a close operating peer to Verastem’s ovarian cancer commercial launch plus KRAS pipeline setup.
FBRX	Forte is a loose early-stage biotech comparator for balance-sheet and catalyst volatility, though it lacks direct product-launch or oncology indication comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-08

AI Stock Memo: VSTM - Verastem - RankAlpha